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Abstract
Introduction: Juvenile idiopathic arthritis (JIA) is characterized by synovial inflammation, followed by hyperplastic
changes of the synovium, and destruction of articular cartilage along with underlying bone. This hyperplastic
process is the result of inflammation-induced activation of NF-B, which may be accompanied by decreased
osteogenic differentiation of synovial mesenchymal progenitors and contribute to bone resorption. We aimed to
explore osteoblast differentiation of synovial fluid (SF)-derived mesenchymal progenitors and correlate it with
intensity of inflammation in patients with JIA.
Methods: Peripheral blood from 18 patients with oligoarticular (o)JIA, 22 patients with polyarticular (p)JIA and 18
controls was collected along with SF from 18 patients with oJIA and 9 patients with pJIA. SF-derived cells were
cultured to assess osteoblastogenesis, using alkaline phosphatase histochemical staining and colorimetric activity
assay. The expression of osteoblast-related genes, Runt-related transcription factor 2 (Runx2), Osteoprotegerin (OPG),
Receptor activator of nuclear factor B ligand (RANKL) and arthritis-related cytokine/chemokine genes, Tumor
necrosis factor alpha (TNF-a, Fas, Fas ligand (FasL), Interleukin (IL)-1b, IL-4, IL-6, IL-17, IL-18, CC chemokine ligand
(CCL)-2, CCL3, CCL4 was evaluated. Osteoblastogenesis was correlated with systemic and local inflammatory
indicators. Expression of osteoblast genes was also analyzed in peripheral blood mononuclear cells (PBMC) and
total SF-derived cells from patients with JIA. Additionally, we assessed the inhibitory effect of SF from patients with
JIA on differentiation of human bone marrow (hBM)-derived osteoblasts.
Results: Osteoblastogenesis from SF-derived progenitors was decreased in patients with pJIA compared to those
with oJIA. Osteoblastogenesis from primary SF-derived cells negatively correlated with erythrocyte sedimentation
rate (r = -0.391, P = 0.05), C-reactive protein concentration (r = -0.527, P<0.01) and synovial concentration of IL-17
(r = -0.552, P = 0.01). SF-derived osteoblasts from pJIA patients expressed more CCL2 and CCL3 genes than in oJIA
(P = 0.04 and P = 0.03, respectively; Mann-Whitney test). Expression of Fas was significantly higher in osteoblasts
from patients with pJIA than those with oJIA (P = 0.03, Mann-Whitney test). SF-derived cells from patients with
pJIA expressed higher levels of RANKL than in oJIA (P = 0.05, Mann-Whitney test). PBMCs from patients with JIA
expressed less OPG than healthy control patients (P = 0.05, Kruskal-Wallis test). SF from all tested JIA patients
inhibited differentiation of hBM-derived osteoblasts (P = 0.04, Kruskal-Wallis test).
Conclusions: Osteoblast differentiation was decreased in patients with severe forms of JIA and accompanied by
altered cytokine/chemokine expression pattern. Development of therapeutic interventions targeting synovial
mesenchymal or osteoblast lineage cells in JIA would contribute to alleviating both bone destruction and
inflammation in severe forms of the disease.
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Introduction
Juvenile idiopathic arthritis (JIA) is one of the leading
causes of disability in children, characterized by synovial
hyperplasia and formation of pannus, which cause
destruction of articular cartilage and underlying bone
[1,2]. Clinically, JIA is defined as arthritis appearing
before 16 years of age, with a minimum duration of six
or more weeks and exclusion of other forms of child-
hood arthritis [3]. According to the International League
of Associations for Rheumatology (ILAR) JIA is classi-
fied into the following subtypes: systemic JIA, oligoarti-
cular JIA (oJIA, affecting four or fewer joints),
polyarticular JIA (pJIA, affecting five or more joints),
psoriatic arthritis, enthesitis-related arthritis and undif-
ferentiated arthritis [3]. In general, oJIA is the most fre-
quent disease form (56 to 60% of cases), followed by
pJIA (28 to 30%). The course of disease is variable;
patients with oJIA have the best outcome, while the
course of pJIA is characterised by progressive and dif-
fuse joint involvement and early radiographic changes.
The pathogenesis of bone loss in children with JIA
involves inflammation, physical inactivity, medication
intake and malnutrition [4]. Inflammation-induced bone
loss in JIA is driven by the interactions of the immune
system and bone, which share a number of regulatory
molecules [5]. The stimulatory effects of inflammation
on osteoclast-mediated bone resorption are well estab-
lished but the influence of pro-inflammatory cytokines
on osteoblast function in vivo requires further elucida-
tion [6]. It is known that tumor necrosis factor (TNF)
and interleukin (IL)-1b may directly impair osteoblast
differentiation [7-10]. Bone marrow-derived mesenchy-
mal stem cells (MSC) from TNF transgenic mice, that
develop chronic inflammatory arthritis, form fewer
osteoblast colonies with decreased expression of osteo-
blast genes [11]. In addition, pro-inflammatory factors
are able to disrupt the Wnt signaling pathway, which
normally induces the differentiation and maturation of
osteoblasts [12,13]. Among Wnt antagonists, murine
models revealed that Dickkopf and secreted Frizzled-
related proteins are upregulated in arthritic synovial tis-
sues and may contribute to decreased osteoblast func-
tion [14]. Inhibition of Dickkopf-1 was able to reverse
bone destruction towards bone formation in the mouse
model of rheumatoid arthritis (RA) [12]. The involve-
ment of Fas and Fas ligand (FasL) has also been pro-
posed in osteoblast differentiation, and confirmed in
animal models of Fas deficiency, which is found to pro-
tect animals from osteoporosis and joint destruction in
arthritis [15-17].
Therapeutic treatment of joint destruction in JIA aims
to attenuate inflammation and bone resorption, as well
as to increase regeneration of subchondral bone and
cartilage. Several therapeutic approaches involve MSC
because of their immunomodulatory and regenerative
capacity [18]. MSC are multipotent cells with ability to
differentiate into osteoblasts, chondroblasts, adipocytes,
connective tissue fibroblasts and myoblasts, thus contri-
buting to tissue regeneration [18]. They are present in
various tissues such as bone marrow, skin, adipose and
connective tissues, as well as the synovia [19,20].
In a murine model, synovial hyperplasia develops as a
result of inflammation-induced activation of nuclear fac-
tor B (NF-B) in synovial fibroblasts, which promotes
their proliferation and inhibits osteoblast/chondroblast
lineage differentiation [21,22]. This mechanism could
also be relevant for human JIA, promoting inflammation
and suppressing joint regeneration.
The overall aim of the present study was to assess the
osteoblastogenesis from synovial fluid (SF)-derived cells
in patients with JIA and its association with disease type
and activity. We first assessed osteoblastogenesis and
osteoblast gene expression in SF-derived cells from
patients with JIA and correlated them with systemic and
local inflammatory activity. We also assessed the sys-
temic expression of osteoblast-related genes in patients
with JIA and control patients, as well as cytokine and
chemokine expression in osteoblasts from JIA patients.
Finally, we investigated the effect of SF from patients




A total of 40 children (29 girls and 11 boys, Table 1),
admitted to the Division of Paediatric Rheumatology of
University Hospital Centre Zagreb, between December
2008 and December 2010 with the diagnosis of JIA,
were included in the study after obtaining approval
Table 1 Demographic and laboratory data for juvenile
idiopathic arthritis (JIA) patients and controls*






Age, years 7.33 ± 5.22 7.13 ± 5.20 11.36 ± 4.50
Male/Female 6/12 4/14 7/15
ESR (1 h) 8.33 ± 4.27 16.44 ± 9.46 53.09 ±
41.03
CRP (g/L) 4.39 ± 6.80 4.34 ± 6.36 47.31 ± 46.3
Leukocyte number
(x109/L)
6.54 ± 1.65 10.03 ± 4.01 9.57 ± 4.62




*Values are mean ± standard deviation. Patients were subdivided into
oligoarticular (oJIA) or polyarticular (pJIA) group according to the International
League of Associations for Rheumatology (ILAR) criteria [3]. ESR, erythrocyte
sedimentation rate; CRP, C-reactive protein; Hb, hemoglobin.
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from the regional Ethics Committee and informed con-
sent from patients. oJIA was diagnosed in 18 and pJIA
in 22 children, in accordance with the ILAR criteria [3].
Eight patients with oJIA and ten patients with pJIA did
not receive any therapy at the time of sampling, and the
others received non-steroid anti-inflammatory drugs
(NSAID) (5 patients each with oJIA and pJIA); disease
modifying anti-rheumatic drugs (DMARDs) - metho-
trexate (MTX) (5 oJIA, 4 pJIA); anti-TNF - etanercept
(1 pJIA) or MTX + prednisone (2 pJIA).
Disease activity was followed by clinical examination
and laboratory assessment (Table 1).
Healthy children without history of autoimmune or
joint diseases, admitted to the Division due to non-
inflammatory conditions during the same period were
also included in the study as controls (n = 18, 12 girls
and 6 boys, Table 1) after obtaining informed consent.
Peripheral blood was obtained from patients and con-
trols during routine clinical assessment, followed by per-
ipheral blood mononuclear cell (PBMC) separation
using Histopaque (Sigma-Aldrich, St. Louis, MO, USA).
All participants’ samples were obtained in the morning
after overnight fasting. In addition, SF samples were col-
lected at the same time from children with JIA with
indication for arthrocentesis (18 patients with oJIA and
9 patients with pJIA), and synovial cells were separated
by centrifuging. Serum and SF samples were collected in
aliquots of 500 μL and stored at -20°C until used. Rou-
tine laboratory tests were performed at the Department
of Clinical Laboratory Diagnostics of the same Hospital
Center.
Osteoblast differentiation from synovial fluid-derived cells
SF-derived cells were cultured in a density of 0.75 × 106
cells/cm2 in 24-well plates in minimal essential med-
ium-a (a MEM) supplemented with 10% fetal bovine
serum (FBS). Osteoblast differentiation was induced on
culture day 7 by the addition of 50 μg/mL ascorbic acid
and 5 mM b-glycerophosphate, and assessed on culture
day 21 by alkaline phosphatase (AP) histochemical stain-
ing using a commercially available kit (Sigma Aldrich,
Milwaukee, MI, USA). Since colonies formed by SF-
derived cells were poorly delineated and confluent, the
area with the red staining was measured by image-ana-
lyzing custom made software for quantification of osteo-
blast differentiation. Total cellularity in each well was
estimated by staining with methylene blue (MB), and
quantified as the area of blue stain using the same soft-
ware. Osteoblast differentiation was additionally assessed
by measuring expression of osteoblast-specific genes on
culture days 14 and 21 by real-time polymerase chain
reaction (PCR). To expand SF-derived mesenchymal
progenitors and remove inflammatory and hematopoie-
tic cells from the culture, adherent cells were passaged
three times, and osteoblastogenesis was induced only in
the fourth passage (P4) cells by plating 0.5 × 105 cells/
cm2 in a-MEM/10% FBS in 24-well plates and addition
of 50 μg/mL ascorbic acid and 5 mM b-glyceropho-
sphate on culture day 2. Assessment of osteoblast differ-
entiation was performed on day 14 by AP histochemical
staining using a commercially available kit (Sigma
Aldrich), and expression of osteoblast genes on culture
days 10 and 14 by real-time PCR. Total cellularity in
each well was estimated by staining with MB. Osteoblast
differentiation was quantified by AP activity colorimetric
assay (Sigma Aldrich), reflecting the number of active
osteoblasts per well.
The time points for gene expression analysis were
determined in a preliminary set of experiments by mul-
tiple time point analysis of expression of differentiation
genes in human primary and P4 SF-derived osteoblasts.
Based on these data, we chose optimal time points
which reflected immature and mature stage of osteoblast
differentiation.
Bone marrow osteoblast culture
Normal hBM was obtained from a healthy donor after
obtaining approval from the regional Ethics Committee
and informed consent from the patient. The 2 × 106
cells were plated in 75 cm2 flasks and cultured in a-
MEM medium supplemented with 10% FBS until reach-
ing confluence. After two passages, 5 × 103 cells/cm2
were plated in a 24-well culture plate. After reaching
confluence, control cells were grown in a-MEM/10%
FBS, 50 μg/mL ascorbic acid and 5 mM b-glyceropho-
sphate for 17 days. Additionally, cells were cultured with
10% SF from oJIA or pJIA patients. Osteoblastogenesis
was assessed by AP activity colorimetric assay (Sigma
Aldrich) and expression of osteoblast genes by real-time
PCR.
Alkaline phosphatase colorimetric assay
For the AP activity assay, total cells from two wells pla-
ted in a density of 0.75 × 106 cells/cm2 for primary cul-
tures, and 0.5 × 105 cells/cm2 for P4 cultures, were
pooled for analysis. Upon removal of cell culture media,
cells were washed 3 times with phosphate-buffered sal-
ine (PBS) and lysed with 200 μL lysing buffer (10 mM
Tris, 0.1% Triton X-100, pH 7.5) per well. AP activity
was measured in a 96-well plate. Five μL of the sample
and 15 μL of lysing buffer were added in duplicates into
each well, together with 180 μL p-nitrophenyl phosphate
(pNP) solution (Sigma Aldrich) and incubated for 30
minutes at 37°C. Color development was measured at
405 nm using the enzyme-linked immunosorbent assay
(ELISA) microplate reader (Bio-Rad, Hercules, CA,
USA). Results were expressed as micromoles of pNP per
hour.
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Gene expression
Total RNA was extracted from peripheral blood cells
and SF-derived cells using 6100 Nucleic Acid PrepSta-
tion (Applied Biosystems, Foster City, CA, USA). For
PCR amplification, 1 μg of total RNA was converted to
complementary DNA (cDNA) by reverse transcriptase
(Applied Biosystems). The amount of cDNA corre-
sponding to 20 ng of reversely transcribed RNA was
amplified by real-time PCR. Expression of glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH), runt-related
transcription factor 2 (Runx2), osteoprotegerin (OPG),
receptor activator of NF-B ligand (RANKL), TNF-a,
Fas, Fas ligand, IL-1b, IL-4, IL-6, IL-17, IL-18, CC che-
mokine ligand (CCL) 2, CCL3, and CCL4 was analyzed
using commercially available TaqMan Assays (Applied
Biosystems).
Real-time PCR was conducted using the ABI Prism
7500 Sequence Detection System (Applied Biosystems).
Each reaction was performed in duplicate in a 25 μL
reaction volume. The relative quantities were calculated
using the standard curve designed from 6 serial dilutions
of the calibrator sample (control PBMC, SF-derived cells
or osteoblast culture cells). According to the standard
curve, the relative amounts of messenger RNA for target
genes were calculated as the ratio of the quantity of the
target gene normalized to GAPDH as the endogenous
control.
ELISA
The concentration of IL-17 and TNF-a in SF was deter-
mined using a commercial kit (Quantikine, Human IL-
17 Immunoassay and Quantikine High Sensitivity,
Human TNF-a Immunoassay, R&D systems, Minneapo-
lis, MN, USA). Briefly, samples were added to anti-IL-17
or anti-TNF-a monoclonal antibody-precoated plates
and incubated for 2 or 3 hours respectively at room
temperature, washed five times and incubated for the
next 2 hours with horseradish peroxidase conjugated IL-
17 or AP-conjugated TNF-a-specific Ab. After five
further washes, the reaction was visualized with sub-
strate solution (tetramethylbenzidine) for IL-17 or sub-
strate and amplifier solutions (NADPH and amplifier
enzymes) for TNF-a, and arrested with hydrochloric or
sulfuric acid respectively. Optical density was deter-
mined within 15 minutes, on the microplate reader
(Bio-Rad, Hercules, CA, USA) set to the excitation
wavelength at 450 nm or 490 nm respectively.
Statistical analysis
Clinical and laboratory data for each type of arthritis
were presented as mean ± standard deviation (SD) and
compared using analysis of variance. AP activity, AP
staining intensity, and gene expression values in JIA and
control samples were expressed as median with
interquartile range (IQR) and compared using the non-
parametric Kruskal-Wallis test followed by the Mann-
Whitney test and Bonferroni’s correction for multiple
testing. Osteoblast differentiation parameters were addi-
tionally correlated to inflammation markers using rank
correlation and Spearman’s coefficient rho (r) with its
95% confidence interval (CI). Statistical analysis was per-
formed using the MedCalc software package (Maria-
kerke, Belgium). For all experiments, the a-level was set
at 0.05.
Results
Osteoblast differentiation from synovial fluid-derived cells
in patients with JIA
SF-derived cells from oJIA formed more AP-positive,
osteoblast-like colonies than SF-derived cells from
patients with pJIA when plated at the same density (Fig-
ure 1A, B). At the same time, total cellularity assessed
by MB staining was also higher in cultures of SF-derived
cells from patients with oJIA in comparison to those
with pJIA, (median 11.49, IQR 8.23 to 12.82 vs. median
5.23, IQR 0.43 to 6.47, arbitrary units/cm2, P = 0.004,
Mann-Whitney test). Similar findings were observed in
osteoblastogenic cultures from adherent SF-derived cells
after removal of inflammatory cells by cell passaging
(P4-cells). As the difference in the histochemical stain-
ing intensity was not so prominent in P4 cultures, since
P4-cells grew in homogenous monolayers (Figure 1C),
we used AP activity colorimetric assay to quantitatively
assess osteoblast differentiation. AP activity was signifi-
cantly higher in osteoblastogenic cultures from patients
with oJIA, than in those with pJIA (Figure 1D). When
P4-cells from patients with oJIA were plated at equal
densities, total cellularity (MB staining, Figure 1C) was
higher than in patients with pJIA (median 11.09, IQR
6.52 to 12.10 vs. median 2.41, IQR 1.74 to 5.91, arbitrary
units/cm2, P = 0.04, Mann-Whitney test).
In addition, the second passage was efficient only in 4
out of 9 pJIA patients, significantly less in comparison
to oJIA patients (16 out of 18, Fisher’s exact test, P =
0.0235).
Inhibition of osteoblast differentiation was confirmed
at the level of osteoblast gene expression as the early
osteoblast marker Runx2, essential for osteoblast differ-
entiation [23], was significantly decreased in pJIA on
day 14 of the primary SF-derived osteoblast culture (P =
0.02, Mann-Whitney test; Figure 2A, Table 2), and day
10 of P4-SF-derived cell culture (P = 0.02, Mann-Whit-
ney test; Figure 2B). OPG gene expression, the marker
of mature osteoblasts, was significantly decreased in
pJIA on day 21 of the primary SF-derived osteoblast cul-
ture (P = 0.03, Mann-Whitney test; Figure 2A, Table 2),
and day 14 of the P4-SF-derived cell culture (P = 0.01,
Mann-Whitney test; Figure 2B, Table 2). Expression of
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RANKL was significantly lower in pJIA only on culture
day 10 in P4-SF-derived osteoblast culture (P = 0.04
Mann-Whitney test; Figure 2B, Table 2).
Expression of osteoblast genes in synovial fluid-derived
cells and peripheral blood mononuclear cells from
patients with JIA
Primary SF-derived cells from patients with oJIA and
pJIA had similar expression of the early osteoblast
marker Runx2, as well as the late osteoblast marker
OPG gene (Figure 3A). Expression of RANKL was signif-
icantly higher in patients with pJIA than in patients with
oJIA (P = 0.05, Mann-Whitney test; Figure 3A). PBMCs
from patients with JIA expressed less OPG than healthy
control patients (P = 0.05, Kruskal-Wallis test: Figure
3B), whereas there was no difference in the expression































































Figure 1 Differentiation of osteoblasts from primary synovial fluid (SF)-derived cells and SF-derived fibroblasts from the fourth
passage (P4), from patients with oligoarticular juvenile idiopathic arthritis (oJIA) and polyarticular JIA (pJIA). Osteoblast differentiation
was induced by ascorbic acid and b-glycerophosphate, and assessed by alkaline phosphatase (AP) histochemical staining. Total fibroblastic
colonies were visualized with methylene blue (MB). (A) Osteoblast and total colonies from representative primary SF-derived cells from children
with oJIA and pJIA stained for AP and MB on culture day 21. (B) AP-stained area (median and interquartile range (IQR), lines represent minimum
and maximum values) in osteoblast cultures grown from primary SF-derived cells from children with oJIA (n = 18) and pJIA (n = 9); * P < 0.05
vs. oJIA group, Mann-Whitney test. (C) Osteoblast and total colonies from representative SF-derived fibroblast samples from the fourth passage
(P4) of SF-derived cells from children with oJIA (n = 7) and pJIA (n = 4) stained for AP and MB on culture day 14. (D) AP activity measured at
day 14 in osteoblast cultures derived from P4 SF-derived fibroblast population (median and IQR);* P < 0.05 vs. oJIA, Mann-Whitney test).
Lazić et al. Arthritis Research & Therapy 2012, 14:R139
http://arthritis-research.com/content/14/3/R139
Page 5 of 12
Osteoblast differentiation negatively correlated with
systemic and local inflammatory indicators
As estimated by the area of the red stain of AP-histo-
chemically positive colonies, SF-derived osteoblast dif-
ferentiation negatively correlated with erythrocyte
sedimentation rate (ESR, P = 0.05, rank correlation; Fig-
ure 4A). The correlation was stronger for C-reactive
protein (CRP, P < 0.01, rank correlation; Figure 4A).
Furthermore, osteoblast differentiation negatively corre-
lated with local synovial concentration of IL-17 (P =
0.01, rank correlation; Figure 4B), an inflammatory cyto-
kine closely related to the development of bone erosions
and produced by Th17 cells, which are enriched in
joints of children with arthritis [24,25]. The inverse rela-
tion was also found between synovial concentrations of
TNF-a and osteoblastogenesis from SF-derived progeni-
tors, although the correlation was not statistically signifi-
cant (P = 0.34, rank correlation; Figure 4B). Finally,
osteoblast differentiation negatively correlated with
expression of the CCL2 gene in SF-derived cells (P =
0.05, rank correlation; Figure 4B).
Expression of cytokines and chemokines in osteoblasts
from patients with JIA
Mesenchymal lineage cells, as well as differentiating and
mature osteoblasts, are known to have immunoregula-
tory properties, expressing various pro- or anti-inflam-
matory cytokines and chemokines [26]. We assessed
gene expression of several candidate cytokines and che-
mokines which could be involved in the regulation of
inflammation in the course of JIA.
The expression of pro-inflammatory CCL2 was signifi-
cantly higher in synovia-derived immature osteoblasts
from patients with pJIA in comparison those with oJIA
(P = 0.04, Mann-Whitney test; Figure 5). The expression
of CCL3 (macrophage inhibitory protein (MIP)1a) was
significantly higher in mature SF-derived osteoblasts
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Figure 2 Real time PCR analysis of expression of early (Runx2) and late (OPG, RANKL) osteoblast genes in synovial fluid (SF)-derived
osteoblasts. (A) Primary SF-derived osteoblastogenic cultures from children with oligoarticular form of juvenile idiopathic arthritis (oJIA, n = 12)
and polyarticular form of JIA (pJIA, n = 4) at culture days 14 and 21 (median and interquartile range (IQR), * P < 0.05 vs. pJIA, Mann-Whitney
test). (B) Osteoblastogenic cultures from the fourth passage (P4) of SF-derived cells from children with oJIA (n = 7) and pJIA (n = 4), at culture
days 10 and 14 (median and IQR,* P < 0.05 vs. pJIA, Mann-Whitney test). mRNA expression was calculated according to the standard curve for
each gene expression in the calibrator sample (cDNA from osteoblast cultures) and normalized to the mRNA quantity for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (endogenous control). OPG, osteoprotegerin; RANKL, receptor activator of NF-B ligand; Runx2, runt-related
transcription factor 2.
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Mann-Whitney test; Figure 5). Fas was significantly
increased in mature SF-derived osteoblasts in patients
with pJIA compared with oJIA (P = 0.03, Mann-Whit-
ney test; Figure 5). Expression of TNF-a, IL-4, IL-6, IL-
17 and IL-18 was not detected in SF-derived osteoblasts,
and expression of CCL4, IL-1b and FasL was not differ-
ent between the groups.
Effect of synovial fluid from patients with JIA on
differentiation of human bone marrow-derived
osteoblasts
To assess whether soluble factors from SF of patients
with JIA could inhibit differentiation of osteoblasts, we
treated BM-derived osteoblasts obtained from a healthy
donor with 10% of SF obtained from patients with JIA,
and compared osteoblast differentiation with untreated
BM osteoblast culture. Assessed by AP activity assay, SF
from both oJIA and pJIA patients inhibited the differen-
tiation of hBM-derived osteoblasts (P < 0.01, Kruskal-
Wallis test; Figure 6A). The specificity of this effect was
confirmed by inhibited expression of Runx2 in early
osteoblastogenic culture (P = 0.04, Kruskal-Wallis test;
Figure 6B).
Discussion
The results of our study clearly demonstrate that osteo-
blastogenesis from SF-derived progenitors was impaired
in patients with pJIA in comparison to patients with
oJIA. Osteoblastogenesis from SF-derived progenitors
correlated with systemic and local inflammatory indica-
tors, suggesting the impact of inflammation on bone
formation.
Decreased osteoblast differentiation was confirmed by
the decreased area of AP-positive osteoblast colonies in
SF-derived osteoblastogenic cultures from JIA patients,
as well as the decreased expression of Runx2, a tran-
scription factor essential for the commitment of
mesenchymal progenitors to the osteoblast lineage [23].
We also assessed gene expression levels of RANKL and
OPG, associated with osteoblast maturation and, at the
same time, important for the regulation of osteoclastic
bone resorption [27,28]. Decreased expression of OPG
in SF-derived osteoblasts from patients with pJIA,
together with comparable expression of RANKL in both
patient groups, resulted in the lower OPG/RANKL ratio
in children with pJIA, which might contribute to the
increase in osteoclastic bone resorption. On the other
Table 2 Osteoblast gene expression in primary and fourth passage (P4) SF-derived osteoblast cultures from patients
with juvenile idiopathic arthritis*
Primary cultures
Gene oJIA (n = 12) pJIA (n = 4)
Day 14 Day 21 Day 14 Day 21
Runx2 0.02 (0.01-0.07) 0.05 (0.02-0.11) 0.00 (0.00-0.01) 0.02 (0.00-0.05)
P (vs. pJIA) 0.02 0.18
P (vs. day 21) 0.20 0.34
OPG 1.63 (0.39-5.65) 13.99 (8.22-21.82) 0.68 (0.40-1.48) 1.52 (0.50-5.68)
P (vs. pJIA) 0.47 0.03
P (vs. day 21) 0.001 0.49
RANKL 0.08 (0.00-0.16) 0.18 (0.04-0.50) 0.12 (0.03-0.20) 0.16 (0.06-0.20)
P (vs. pJIA) 0.54 0.90
P (vs. day 21) 0.42 0.89
P4 cultures
oJIA (n = 7) pJIA (n = 4)
Day 10 Day 14 Day 10 Day 14
Runx2 0.04 (0.02-0.08) 0.03 (0.02-0.05) 0.02 (0.01-0.02) 0.02 (0.01-0.03)
P (vs. pJIA) 0.02 0.32
P (vs. day14) 0.46 0.20
OPG 0.07 (0.04-0.08) 0.12 (0.08-0.20) 0.04 (0.01-0.06) 0.04 (0.01-0.06)
P (vs. pJIA) 0.23 0.01
P (vs. day14) 0.04 0.89
RANKL 0.01 (0.01-0.03) 0.01 (0.01-0.04) 0.00 (0.00-0.00) 0.01 (0.00-0.01)
P (vs. pJIA) 0.04 0.23
P (vs. day14) 0.53 0.06
*Values are median (interquartile range), statistical differences were calculated using the Mann-Whitney test. Patients were subdivided into the oligoarticular
(oJIA) or polyarticular (pJIA) group according to the International League of Associations for Rheumatology (ILAR) criteria [3]. Day, day of osteoblast culture; OPG,
osteoprotegerin gene; RANKL, receptor activator of NF-B ligand gene; Runx2, runt-related transcription factor 2 gene.
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hand, expression of RANKL was higher in total SF-
derived cells from patients with pJIA compared to those
with oJIA, which may be explained by the fact that
RANKL is produced not only by osteoblasts but also by
activated T lymphocytes [29]. Furthermore, both oJIA
and pJIA patients expressed less OPG in PBMCs than
the control group, which is consistent with the recent
prospective cohort study reporting lower OPG serum
levels, higher levels of RANKL and decreased OPG/
RANKL ratio in children with JIA compared to healthy
children [30].
Since oJIA had lower laboratory inflammation markers
than pJIA, we expected that osteoblastogenesis would be
negatively regulated by inflammatory processes. This
was confirmed by the negative correlation of osteoblas-
togenesis with the levels of CRP and ESR, demonstrating
an osteoblast-related mechanism of bone loss which
accompanies autoimmune disorders [31].
Negative correlation of osteoblastogenesis with syno-
vial IL-17 levels found in patients with JIA is consistent
with IL-17 contribution to the cartilage and bone
damage seen in the animal model of autoimmune
arthritis [24]. IL-17 participates in the arthritic process
by affecting B- and T-lymphocytes, epithelial, myelomo-
nocytic and BM stromal cells and synovial fibroblasts
and chondrocytes, stimulating their production of var-
ious cytokines, chemokines and tissue destructive med-
iators [32,33]. Soluble IL-17 and high numbers of IL-17-
producing Th17 cells have been found in synovial tissue
from adults and children with inflammatory arthritis,
particularly in those with a more severe clinical course
[33,34]. Although we were unable to confirm statistically
significant correlation between synovial TNF-a concen-
tration and SF-derived osteoblasts differentiation, we
observed an inverse relationship between these two vari-
ables. The lack of significance for this correlation is
probably related to high variability of synovial TNF-a
concentration in study patients (13.03 ± 11.08 pg/ml).
In addition, we assessed whether osteoblastogenesis
could be altered by therapy, but we were unable to
detect a significant difference either in osteoblastogen-
esis or in systemic (SE, CRP) and local (synovial TNF-a)
inflammation parameters between patients receiving








































































Figure 3 Real time PCR analysis of expression of osteoblast genes in synovial fluid (SF)-derived cells (A) and peripheral blood
mononuclear cells (PBMC) from patients with oligoarticular form of juvenile idiopathic arthritis (oJIA), polyarticular form of JIA (pJIA),
and control (ctrl) children. (B) mRNA expression was calculated according to the standard curve for each gene expression in the calibrator
sample (cDNA from SF-derived cells or PBMC) and normalized to mRNA quantity for glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(endogenous control). Results are presented as median and interquartile range (IQR) for each group; lines represent minimum and maximum
values; * P ≤ 0.05 vs. oJIA (Mann-Whitney test). PBMC, peripheral blood mononuclear cell; OPG, osteoprotegerin; RANKL, receptor activator of NF-
B ligand; Runx2, runt-related transcription factor 2.
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ascribed to the poor therapeutic response in treated
patients or activation of disease in the untreated patient
group. A more homogenous and larger group of patients
according to the duration of the disease and the applied
therapy is needed to address this issue with adequate
power.
Mesenchymal cells are known to have immunoregula-
tory properties [35]. Upon inflammatory stimuli, osteo-
blasts also may express various cytokines and
chemokines that augment or suppress inflammation.
Synovial inflammation in patients with RA and human
TNF transgenic mice upregulates WNT5A in synovial
fibroblasts [26]. WNT5A is able to induce IL-1b, IL-6,
CCL2, CCL5, CXCL1, and CXCL5 in osteoblasts, thus
altering their regulatory properties [26]. It has been pre-
viously shown that osteoblasts and osteocytes from RA
patients immunohistochemically expressed CCL20,
which was absent in osteoblasts from osteoarthritic
patients [36]. We demonstrated that the expression of
CCL2 was higher in SF-derived immature osteoblasts
from patients with pJIA, whereas CCL3 expression was
increased in mature SF-derived osteoblasts derived from
patients with pJIA. In the animal model of adjuvant
arthritis, CCL2 and CCL3, up-regulated by TNF and IL-
1b, are shown to contribute to the pathogenesis of
inflammatory arthritis [37]. Our finding of increased
proinflammatory CCL2 and CCL3 in osteoblasts derived
from pJIA patients suggests that osteoblastic cells in
severe forms of JIA may themselves perpetuate joint
inflammation via cytokine secretion. In addition, the
expression of Fas, a TNF superfamily member charac-
teristic for T lymphocytes but also expressed on osteo-
blasts and osteoclast lineage cells [38], was increased in
mature SF-derived osteoblasts from pJIA patients. We
have previously described that Fas expressed by mature
murine osteoblasts is able to specifically inhibit their dif-
ferentiation [15]. This mechanism could also be effective
in human JIA and lead to suppressed osteoblasts differ-
entiation as a result of inflammatory process in JIA.
Our study also provides experimental evidence that SF
from patients with both oJIA and pJIA may adversely
influence the differentiation of hBM derived osteoblasts.
Together with the in vitro finding of Caparbo, et al. [39]
that serum from patients with active pJIA decreases dif-
ferentiation and increases apoptosis in human osteo-
blasts, our study experimentally demonstrated that bone
loss in JIA was associated with decreased osteoblasto-















































































































Figure 4 Correlation of alkaline phosphatase (AP) staining with inflammatory parameters. (A) Systemic inflammatory parameters:
erythrocyte sedimentation rate (ESR) and C reactive protein (CRP). (B) Local inflammatory parameters: synovial concentration of interleukin (IL)-17
and TNF-a; and CCL2 mRNA expression in synovial fluid (SF)-derived cells. Values were correlated using rank correlation and Spearman’s
coefficient r (95% confidence interval for r).
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Day of cell culture
Figure 5 Expression of chemokines CCL2, CCL3, CCL4, and IL-1b, Fas and Fas ligand (FasL) genes in primary synovial fluid (SF)-derived
osteoblastogenic cultures. Cultures were derived from children with oligoarticular juvenile idiopathic arthritis (oJIA, n = 12) or polyarticular JIA
(pJIA, n = 4) and gene expression analyzed at culture days 14 and 21 (median and interquartile range (IQR), *P < 0.05 vs. oJIA, Mann-Whitney
test). mRNA expression was calculated according to the standard curve for each gene expression in the calibrator sample (cDNA from osteoblast
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Figure 6 Effect of synovial fluid from patients with oligoarticular form of juvenile idiopathic arthritis (oJIA) and polyarticular form of
JIA (pJIA) on the differentiation of osteoblasts from normal human bone marrow (BM) progenitors. Osteoblastogenesis was induced by
ascorbic acid and b-glycerophosphate. Synovial fluid from patients with oJIA or pJIA was added to osteoblastogenic culture with each medium
exchange. Osteoblastogenesis was assessed by AP activity and expression of Runx2 gene by real time PCR. (A) AP activity measured at day 7 and
17 in control cultures (hBM) and cultures supplemented with 10% synovial fluid from children with oJIA (hBM + oJIA SF) and pJIA (hBM + oJIA
SF, * P < 0.05 vs. control group, Mann-Whitney test). (B) Expression of Runx2 gene in control cultures (hBM) and cultures supplemented with
synovial fluid from children with oJIA (hBM + oJIA SF) and pJIA (hBM + pJIA SF). mRNA expression was calculated according to the standard
curve for each gene expression in the calibrator sample (cDNA from osteoblastogenic cultures) and normalized to the mRNA quantity for
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (endogenous control). Results are expressed as median and interquartile range (IQR) for
each group; lines represent minimum and maximum values. AP, alkaline phosphatase; hBM, human bone marrow.
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may be the cellular mechanism for lower levels of bone
formation biochemical markers found in JIA patients
[40,41].
Conclusions
In conclusion, decreased osteoblast differentiation is
accompanied by altered properties of SF-derived osteo-
blasts from patients with severe forms of JIA, which
may promote osteoclastic bone resorption and perpetu-
ate local and systemic inflammation. Development of
therapeutic interventions targeting synovial mesenchy-
mal and/or osteoblast lineage cells in JIA would contri-
bute to alleviating both bone destruction and
inflammation in severe forms of the disease.
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